Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 669

1.

Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.

J Stroke Cerebrovasc Dis. 2012 Apr;21(3):165-73. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011. Review.

PMID:
22440950
2.

[Dabigatran, a new oral anticoagulant].

Uchiyama S.

Brain Nerve. 2011 Apr;63(4):411-5. Review. Japanese.

PMID:
21441645
3.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
4.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
5.

[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].

Szapary L, Fehér G, Bosnyák E, Deli G, Csécsei P.

Ideggyogy Sz. 2013 May 30;66(5-6):165-74. Review. Hungarian.

PMID:
23909016
6.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
7.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

8.

Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.

Galanis T, Merli GJ.

Hosp Pract (1995). 2013 Feb;41(1):26-36. doi: 10.3810/hp.2013.02.1010. Review.

PMID:
23466965
9.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.

Berman JP, Halperin JL.

Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006. Review.

PMID:
23466966
10.

Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.

Paikin JS, Haroun MJ, Eikelboom JW.

Expert Rev Cardiovasc Ther. 2011 Mar;9(3):279-86. doi: 10.1586/erc.11.21.

PMID:
21438804
11.

Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.

Chevalier J, Giroud M, de Pouvourville G.

Cerebrovasc Dis. 2013;35(4):320-6. doi: 10.1159/000347074. Epub 2013 Apr 23.

PMID:
23615428
12.

Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents.

Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, Kamakura S, Kumagai K, Mitamura H, Okumura K, Sugi K, Yamashita T.

Circ J. 2011;75(7):1539-47. Epub 2011 Jun 9. Review.

13.

Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.

Lenchus JD.

Hosp Pract (1995). 2013 Feb;41(1):49-60. doi: 10.3810/hp.2013.02.1007.

PMID:
23466967
14.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

15.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.

Contractor T, Levin V, Martinez MW, Marchlinski FE.

Postgrad Med. 2013 Jan;125(1):34-44. doi: 10.3810/pgm.2013.01.2622. Review.

PMID:
23391669
16.

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.

Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.

17.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
18.

Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.

Destephan C, Waller AH, Patel RJ, Dhruvakumar S, Mazza V, Gerula C, Maher J, Kaluski E.

Minerva Cardioangiol. 2012 Aug;60(4):425-31. Review.

PMID:
22858920
19.

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ.

Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Review.

PMID:
23322134
20.

New anticoagulants for prevention of stroke in patients with atrial fibrillation.

Viles-Gonzalez JF, Fuster V, Halperin JL.

J Cardiovasc Electrophysiol. 2011 Aug;22(8):948-55. doi: 10.1111/j.1540-8167.2011.02104.x. Epub 2011 Jun 10. Review.

PMID:
21668558

Supplemental Content

Support Center